search
Back to results

Outpatient Pediatric Pulse Oximeters in Africa

Primary Purpose

Child, Infant, Respiratory Tract Infections

Status
Not yet recruiting
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Phefumla device
LB-01 device
Sponsored by
Johns Hopkins University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Child

Eligibility Criteria

0 Months - 59 Months (Child)All SexesDoes not accept healthy volunteers

Inclusion Criteria: 0-59 months of age inclusive presenting to care for an acute condition the includes observed and/or caregiver history of either cough and/or difficult breathing residing in clinic catchment area caregiver agrees to provide contact details including phone number and/or residential address caregiver agrees to be contacted after two weeks by the study staff caregiver is able and willing to provide written informed consent Exclusion Criteria: 60 months of age or older presenting to care for a non-acute condition or an acute condition that does not include either observed or caregiver history of cough and/or difficult breathing does not reside in the clinic catchment area caregiver does not agree to provide contact details caregiver does not agree to be contact by study staff after two weeks caregiver unable to provide written informed consent

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm 3

    Arm Type

    No Intervention

    Experimental

    Experimental

    Arm Label

    Controls

    Phefumla

    LB-01

    Arm Description

    Controls will be managed routinely by the clinic staff, including the triage and clinical examination pathway through the facility, treatment and referral decisions, all of which can include the standard care device. After the child has been given a primary diagnosis and decision on onward care (i.e. referral or home-based management), the study data collector will conduct an exit interview. This interview will include the following topics: the clinical examination conducted by the healthcare worker; current intentions for onward care (e.g. are planning to go to hospital, how are the healthcare worker is travelling); extracting clinical information from the patient medical record - including oxygen saturation measurement. Finally, the study data collector will conduct oxygen saturation measurements using the control device and a reference device.

    Phefumla arm participants will be managed by the clinic staff, including the triage and clinical examination pathway through the facility, treatment and referral decisions, all of which can include the Phefumla device. After the child has been given a primary diagnosis and decision on onward care (i.e. referral or home-based management), the study data collector will conduct an exit interview. This interview will include the following topics: the clinical examination conducted by the healthcare worker; current intentions for onward care (e.g. if planning to go to hospital, how is the healthcare worker is travelling); extracting clinical information from the patient medical record - including oxygen saturation measurement. Finally, the study data collector will conduct oxygen saturation measurements using the Phefumla device and a reference device.

    LB-01 arm participants will be managed by the clinic staff, including the triage and clinical examination pathway through the facility, treatment and referral decisions, all of which can include the LB-01 device. After the child has been given a primary diagnosis and decision on onward care (i.e. referral or home-based management), the study data collector will conduct an exit interview. This interview will include the following topics: the clinical examination conducted by the healthcare worker; current intentions for onward care (e.g. are if planning to go to hospital, how is the healthcare worker travelling); extracting clinical information from the patient medical record - including oxygen saturation measurement. Finally, the study data collector will conduct oxygen saturation measurements using the LB-01 device and a reference device.

    Outcomes

    Primary Outcome Measures

    Correct management of oxygen saturation
    The numerator is the number of children who have a biologically plausible oxygen saturation measurement achieved, the oxygen saturation measurement is documented by the healthcare worker, and an appropriate referral recommendation has been provided by the healthcare worker. All three of these conditions need to be met to be considered correct management. The denominator will be all the eligible recruited children, with suspected LRI.

    Secondary Outcome Measures

    Oxygen saturation measurement acceptance
    The proportion of caregivers who permit the healthcare worker to measure the oxygen saturation on the child.
    Referral completion
    Amongst children with an oxygen saturation <94%, the proportion who present to the referral hospital within 48 hours.
    Proportion Who Receive Oxygen treatment
    Amongst children with an oxygen saturation <94%, the proportion who present to the referral hospital within 48 hours and are given oxygen treatment.
    Mortality
    The proportion of children who died from any cause by day 15 of enrollment.
    Hypoxemic (<94%) mortality
    The proportion of children with an oxygen saturation <94% who died by day 15 of enrollment.
    Hypoxemic (<90%) mortality
    The proportion of children with an oxygen saturation <90% who died by day 15 of enrollment.

    Full Information

    First Posted
    June 1, 2023
    Last Updated
    June 12, 2023
    Sponsor
    Johns Hopkins University
    Collaborators
    University of Stellenbosch, Karolinska Institutet, Baylor College of Medicine
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT05914324
    Brief Title
    Outpatient Pediatric Pulse Oximeters in Africa
    Official Title
    Evaluating Novel Pediatric Pulse Oximeters for Outpatient Child Pneumonia Care in Sub-Saharan Africa
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    June 2023
    Overall Recruitment Status
    Not yet recruiting
    Study Start Date
    March 1, 2024 (Anticipated)
    Primary Completion Date
    February 28, 2026 (Anticipated)
    Study Completion Date
    February 28, 2026 (Anticipated)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    Johns Hopkins University
    Collaborators
    University of Stellenbosch, Karolinska Institutet, Baylor College of Medicine

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    No
    Studies a U.S. FDA-regulated Device Product
    No
    Data Monitoring Committee
    Yes

    5. Study Description

    Brief Summary
    The primary objective of this clinical trial is to evaluate the performance of three pulse oximeters during outpatient care within Cape Town, South Africa. This objective will be achieved through generating evidence on how, why, for whom, to what extent and at what cost can paediatric pulse oximetry devices improve the management of hypoxemic children. This will be done with two inter-linked studies: Aim 1: Determine the impact of two novel paediatric pulse oximeter devices on the correct management of hypoxaemia. If the investigators find these devices improve healthcare worker assessments and decision making, it could improve clinical outcomes for children in low-resource contexts. Aim 2: Describe the burden of hypoxaemia and risks for mortality amongst children presenting with acute respiratory infections in a low-resource setting in Cape Town. By establishing the burden and need, a clearer investment case for pulse oximetry can be made for this context.
    Detailed Description
    Background: Lower respiratory tract infections (LRI) remain the leading infectious cause of death globally for children younger than five years.1 Alarmingly, >50% of LRI deaths occurred in low and middle-income countries (LMICs) in sub-Saharan Africa, with inequitable distribution both between and within countries.2 Key quality-of-care implementation gaps have hampered the effectiveness of the World Health Organization (WHO) Integrated Management of Childhood Illnesses (IMCI) guidelines used for pediatric LRI care in LMICs.3 Evaluations of Integrated Management of Childhood Illness (IMCI) guidelines have identified inadequate triaging and therefore results in a failure to identify children at higher risk of death. Interventions to improve the sensitivity and specificity of the IMCI approach in identifying severely ill children could improve outcomes. Routine use of pulse oximetry, to non-invasively measure peripheral oxyhemoglobin saturation (SpO2), is poorly implemented at the primary healthcare (PHC) levels in LMICs, and therefore provides one such opportunity to improve IMCI assessments. Hypoxemia - a low SpO2, is associated with increased mortality in children with LRI(1).4 Hypoxemia prevalence amongst children with pneumonia in African contexts has been estimated at 28%, and in outpatient settings as 23%.5 As hypoxemia is a key mortality risk factor, effectively identifying these children early in the care-seeking pathway is fundamental to reducing mortality in low-resource contexts.6 While SpO2 is recommended by IMCI for children with suspected pneumonia, pulse oximetry devices for measuring SpO2 are not widely implemented in PHCs in LMICs, where most children first access care. In Malawi 16% of nearly 700 outpatient encounters with suspected LRI had a SpO2 measured, and >40% of children eligible for hospitalization were not referred. Since few children have SpO2 collected during outpatient care, referral decisions are largely based on subjective clinical danger signs. This then has knock-on effects on receipt of oxygen treatment. While pulse oximetry implementation in PHCs has been slow to scale-up, there is evidence of utility and feasibility. In Malawi, healthcare workers successfully measured the SpO2 on 94% of >14,000 children and were >2 times more likely to correctly refer a child when the child's SpO2 was low. This work also demonstrated >60% of hypoxemic children would not have been referred in the absence of an SpO2 measurement.7 One explanation for slow adoption is the lack of appropriate devices, that have been designed specifically for spot-checks amongst children in outpatient LMIC settings - a population with specific oximetry needs. Important features of such a device are being low cost, robust, able to cope with poor perfusion and motion artefact, good battery life and reliable.8 Mobile phones are relatively inexpensive, widely available, and increasingly utilized for healthcare - 'mobile Health (mHealth)', while electronic Health (eHealth) is when electronic services - like the internet - support healthcare. In LMICs mobile phones offer the potential for expanded healthcare access and quality of care both as a medical device and as a platform for eHealth services, such as the digital health management information system (HMIS) used in sub-Saharan Africa - District Health Information Software 2 (DHIS2). Developing a mobile-based pulse oximeter, with interoperability to store and upload data directly into a patients DHIS2 record has the potential to improve the management of paediatric hypoxaemia. The Phefumela Project, meaning "breathe" in a local South African language, will evaluate the impact of two different novel paediatric pulse oximeters, both designed specifically for this population in a high burden setting in South Africa. Aim 1: Determine the impact of two novel paediatric pulse oximeter devices on the correct management of hypoxaemia. If the investigators find these devices improve healthcare worker assessments and decision making, it could improve clinical outcomes for children in low-resource contexts. Aim 2: Describe the burden of hypoxaemia and risks for mortality amongst children presenting with acute respiratory infections in a low-resource setting in Cape Town. By establishing the burden and need, a clearer investment case for pulse oximetry can be made for this context. Setting: The study site is the large Khayelitsha community, which includes 6 primary healthcare clinics (PHCs), 2 community health centers (CHCs), 1 community day centers (CDCs) and one government district hospital serving its catchment area, Khayelitsha Hospital. The nearest tertiary referral government hospital is Tygerberg, which serves 40% of the provincial paediatric population. Khayelitsha township has a population of approximately 450,000 and is 90.5% Black African. Khayelitsha has a very young population, with >40% of its residents under 19 years of age, residing in informal housing with high caregiver unemployment and limited running water access. HIV (human immunodeficiency virus) and tuberculosis prevalence is high; maternal HIV prevalence is 29.5% - the highest in the Western Cape Province - and the tuberculosis incidence of 1,389/100,000 population exceeded the national average of 834/100,000 in 2017.9 Khayelitsha Hospital has an average bed occupancy rate over 130% capacity, and its 47 bed emergency center cares for about 120 patients daily. A 2015 study characterized the pediatric case mix over six months at the emergency center, reporting >80% of pediatric patients were <5 years old, nearly 2/3 were triaged at an emergent level, and the most common diagnosis was LRIs (22.0%, n=70/317). Of 58 children with pneumonia, 5 (8.5%) died.9 Pulse oximeter devices: The investigators will be using and comparing three different pulse oximeter devices during this study, two (the Phefumla and Lifebox-01 (LB-01)) are not commercially available. The Contec device is widely available and currently used clinically in this setting in South Africa. Throughout this study, the Contec device will be considered the reference or control standard.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Child, Infant, Respiratory Tract Infections, Hypoxia

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Not Applicable
    Interventional Study Model
    Parallel Assignment
    Model Description
    Pragmatic 3-arm cluster randomised controlled trial (cRCT), conducted over a 24-month period, with a 3-month pilot and 3-month intervention embedding period. Clusters are defined as outpatient facilities (PHC, CDC, CHC), and the primary and secondary child-level outcomes will be assessed through a prospective cohort study. An embedded mixed-methods concurrent process evaluation will be conducted.
    Masking
    InvestigatorOutcomes Assessor
    Masking Description
    Researchers who are responsible for collecting data will not be informed of facility allocation. The key of which facilities are in which arm will be held by Stellenbosch and Johns Hopkins University, and the researcher at Karolinska Institute who will conduct the primary analysis will not have access to this information until after the primary analysis has been done and approved by the Trial Steering Committee. Process and economic evaluation data will also be analysed using a masked code for allocation arm, and only unblinded after the primary analysis is completed.
    Allocation
    Randomized
    Enrollment
    2160 (Anticipated)

    8. Arms, Groups, and Interventions

    Arm Title
    Controls
    Arm Type
    No Intervention
    Arm Description
    Controls will be managed routinely by the clinic staff, including the triage and clinical examination pathway through the facility, treatment and referral decisions, all of which can include the standard care device. After the child has been given a primary diagnosis and decision on onward care (i.e. referral or home-based management), the study data collector will conduct an exit interview. This interview will include the following topics: the clinical examination conducted by the healthcare worker; current intentions for onward care (e.g. are planning to go to hospital, how are the healthcare worker is travelling); extracting clinical information from the patient medical record - including oxygen saturation measurement. Finally, the study data collector will conduct oxygen saturation measurements using the control device and a reference device.
    Arm Title
    Phefumla
    Arm Type
    Experimental
    Arm Description
    Phefumla arm participants will be managed by the clinic staff, including the triage and clinical examination pathway through the facility, treatment and referral decisions, all of which can include the Phefumla device. After the child has been given a primary diagnosis and decision on onward care (i.e. referral or home-based management), the study data collector will conduct an exit interview. This interview will include the following topics: the clinical examination conducted by the healthcare worker; current intentions for onward care (e.g. if planning to go to hospital, how is the healthcare worker is travelling); extracting clinical information from the patient medical record - including oxygen saturation measurement. Finally, the study data collector will conduct oxygen saturation measurements using the Phefumla device and a reference device.
    Arm Title
    LB-01
    Arm Type
    Experimental
    Arm Description
    LB-01 arm participants will be managed by the clinic staff, including the triage and clinical examination pathway through the facility, treatment and referral decisions, all of which can include the LB-01 device. After the child has been given a primary diagnosis and decision on onward care (i.e. referral or home-based management), the study data collector will conduct an exit interview. This interview will include the following topics: the clinical examination conducted by the healthcare worker; current intentions for onward care (e.g. are if planning to go to hospital, how is the healthcare worker travelling); extracting clinical information from the patient medical record - including oxygen saturation measurement. Finally, the study data collector will conduct oxygen saturation measurements using the LB-01 device and a reference device.
    Intervention Type
    Device
    Intervention Name(s)
    Phefumla device
    Intervention Description
    The Phefumla device uses the Motorola Moto G Power mobile phone. The device utilizes an Android 10 operating system and has 64 gigabyte memory with 4 gigabyte random access memory (RAM). The battery is a 5000 milliampere lithium polymer rechargeable battery, which should last at least 24 hours with minimal phone use. Data can be stored on the device and integration with information systems is planned. The reflectance sensor works on a variety of body parts including the finger, toe, and forehead.
    Intervention Type
    Device
    Intervention Name(s)
    LB-01 device
    Intervention Description
    The LB-01 probe uses transmissive oximetry with the light-emitting diode (LED) and photodetector (PD) positioned opposed to one another when placed on body tissues like fingers, and is used with the Acare pulse oximeter device. The LB-01 probe is an elongated clip sensor with an offset optics location near the hinge, permitting stable positioning on the child's big toe. By incorporating softer hollow silicone pads this design grasps the foot while placing the optics over the toe, to minimize movement artifact, an important issue for child measurements. The soft pads allow comfortable use across the smaller foot of neonates, and the design remains similar enough to a conventional finger sensor that it can be used on adult fingers as well.
    Primary Outcome Measure Information:
    Title
    Correct management of oxygen saturation
    Description
    The numerator is the number of children who have a biologically plausible oxygen saturation measurement achieved, the oxygen saturation measurement is documented by the healthcare worker, and an appropriate referral recommendation has been provided by the healthcare worker. All three of these conditions need to be met to be considered correct management. The denominator will be all the eligible recruited children, with suspected LRI.
    Time Frame
    Day 1 after enrollment
    Secondary Outcome Measure Information:
    Title
    Oxygen saturation measurement acceptance
    Description
    The proportion of caregivers who permit the healthcare worker to measure the oxygen saturation on the child.
    Time Frame
    Day 1 after enrollment
    Title
    Referral completion
    Description
    Amongst children with an oxygen saturation <94%, the proportion who present to the referral hospital within 48 hours.
    Time Frame
    Day 3 after enrollment
    Title
    Proportion Who Receive Oxygen treatment
    Description
    Amongst children with an oxygen saturation <94%, the proportion who present to the referral hospital within 48 hours and are given oxygen treatment.
    Time Frame
    Day 3 after enrollment
    Title
    Mortality
    Description
    The proportion of children who died from any cause by day 15 of enrollment.
    Time Frame
    Day 15 after enrollment
    Title
    Hypoxemic (<94%) mortality
    Description
    The proportion of children with an oxygen saturation <94% who died by day 15 of enrollment.
    Time Frame
    Day 15 after enrollment
    Title
    Hypoxemic (<90%) mortality
    Description
    The proportion of children with an oxygen saturation <90% who died by day 15 of enrollment.
    Time Frame
    Day 15 after enrollment

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    0 Months
    Maximum Age & Unit of Time
    59 Months
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: 0-59 months of age inclusive presenting to care for an acute condition the includes observed and/or caregiver history of either cough and/or difficult breathing residing in clinic catchment area caregiver agrees to provide contact details including phone number and/or residential address caregiver agrees to be contacted after two weeks by the study staff caregiver is able and willing to provide written informed consent Exclusion Criteria: 60 months of age or older presenting to care for a non-acute condition or an acute condition that does not include either observed or caregiver history of cough and/or difficult breathing does not reside in the clinic catchment area caregiver does not agree to provide contact details caregiver does not agree to be contact by study staff after two weeks caregiver unable to provide written informed consent
    Central Contact Person:
    First Name & Middle Initial & Last Name or Official Title & Degree
    Eric D McCollum, MD MPH
    Phone
    +27790669233
    Email
    emccoll3@jhmi.edu
    First Name & Middle Initial & Last Name or Official Title & Degree
    Carina King, PhD
    Phone
    +46852480000
    Email
    carina.king@ki.se
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Eric McCollum, MD, MPH
    Organizational Affiliation
    Johns Hopkins School of Medicine
    Official's Role
    Principal Investigator

    12. IPD Sharing Statement

    Plan to Share IPD
    Yes
    IPD Sharing Plan Description
    De-identified data will be made available after publication of the primary analysis. Other researchers who submit a written request to the principal investigator with analysis plan, data sharing agreement, and institutional review board approval will be afforded access to individual participant data.
    IPD Sharing Time Frame
    Data will become available after publication of the primary analysis and will be available for at least 5 years.
    IPD Sharing Access Criteria
    Written request to the principal investigator, analysis plan, data sharing agreement, and institutional review board approval.
    Citations:
    PubMed Identifier
    34416195
    Citation
    GBD 2019 Under-5 Mortality Collaborators. Global, regional, and national progress towards Sustainable Development Goal 3.2 for neonatal and child health: all-cause and cause-specific mortality findings from the Global Burden of Disease Study 2019. Lancet. 2021 Sep 4;398(10303):870-905. doi: 10.1016/S0140-6736(21)01207-1. Epub 2021 Aug 17.
    Results Reference
    background
    PubMed Identifier
    31570869
    Citation
    Reiner RC, Welgan CA, Casey DC, Troeger CE, Baumann MM, Nguyen QP, Swartz SJ, Blacker BF, Deshpande A, Mosser JF, Osgood-Zimmerman AE, Earl L, Marczak LB, Munro SB, Miller-Petrie MK, Rodgers Kemp G, Frostad J, Wiens KE, Lindstedt PA, Pigott DM, Dwyer-Lindgren L, Ross JM, Burstein R, Graetz N, Rao PC, Khalil IA, Davis Weaver N, Ray SE, Davis I, Farag T, Brady OJ, Kraemer MUG, Smith DL, Bhatt S, Weiss DJ, Gething PW, Kassebaum NJ, Mokdad AH, Murray CJL, Hay SI. Identifying residual hotspots and mapping lower respiratory infection morbidity and mortality in African children from 2000 to 2017. Nat Microbiol. 2019 Dec;4(12):2310-2318. doi: 10.1038/s41564-019-0562-y. Epub 2019 Sep 30.
    Results Reference
    background
    Citation
    WHO. World Health Organization Integrated Management of Childhood Illness ( IMCI ) Chart Booklet-Standard. Geneva (Switzerland): World Health Organization 2014; : 1-80.
    Results Reference
    background
    PubMed Identifier
    26372640
    Citation
    Lazzerini M, Sonego M, Pellegrin MC. Hypoxaemia as a Mortality Risk Factor in Acute Lower Respiratory Infections in Children in Low and Middle-Income Countries: Systematic Review and Meta-Analysis. PLoS One. 2015 Sep 15;10(9):e0136166. doi: 10.1371/journal.pone.0136166. eCollection 2015.
    Results Reference
    background
    PubMed Identifier
    35180418
    Citation
    Rahman AE, Hossain AT, Nair H, Chisti MJ, Dockrell D, Arifeen SE, Campbell H. Prevalence of hypoxaemia in children with pneumonia in low-income and middle-income countries: a systematic review and meta-analysis. Lancet Glob Health. 2022 Mar;10(3):e348-e359. doi: 10.1016/S2214-109X(21)00586-6.
    Results Reference
    background
    PubMed Identifier
    27843130
    Citation
    McCollum ED, King C, Hammitt LL, Ginsburg AS, Colbourn T, Baqui AH, O'Brien KL. Reduction of childhood pneumonia mortality in the Sustainable Development era. Lancet Respir Med. 2016 Dec;4(12):932-933. doi: 10.1016/S2213-2600(16)30371-X. Epub 2016 Nov 12. No abstract available.
    Results Reference
    background
    PubMed Identifier
    27994282
    Citation
    McCollum ED, King C, Deula R, Zadutsa B, Mankhambo L, Nambiar B, Makwenda C, Masache G, Lufesi N, Mwansambo C, Costello A, Colbourn T. Pulse oximetry for children with pneumonia treated as outpatients in rural Malawi. Bull World Health Organ. 2016 Dec 1;94(12):893-902. doi: 10.2471/BLT.16.173401. Epub 2016 Oct 11. Erratum In: Bull World Health Organ. 2017 Jan 1;95(1):81.
    Results Reference
    background
    PubMed Identifier
    29382679
    Citation
    King C, Boyd N, Walker I, Zadutsa B, Baqui AH, Ahmed S, Islam M, Kainja E, Nambiar B, Wilson I, McCollum ED. Opportunities and barriers in paediatric pulse oximetry for pneumonia in low-resource clinical settings: a qualitative evaluation from Malawi and Bangladesh. BMJ Open. 2018 Jan 30;8(1):e019177. doi: 10.1136/bmjopen-2017-019177.
    Results Reference
    background
    Citation
    Richards D, Hunter L, Forey K, et al. Demographics and predictors of mortality in children undergoing resuscitation at Khayelitsha Hospital, Western Cape, South Africa. SAJCH South African Journal of Child Health 2018; 12: 127-31
    Results Reference
    background
    PubMed Identifier
    30984733
    Citation
    Glasgow RE, Harden SM, Gaglio B, Rabin B, Smith ML, Porter GC, Ory MG, Estabrooks PA. RE-AIM Planning and Evaluation Framework: Adapting to New Science and Practice With a 20-Year Review. Front Public Health. 2019 Mar 29;7:64. doi: 10.3389/fpubh.2019.00064. eCollection 2019.
    Results Reference
    background

    Learn more about this trial

    Outpatient Pediatric Pulse Oximeters in Africa

    We'll reach out to this number within 24 hrs